The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis

The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis - The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023344

Enrollment

Registered

2016-07-26

Start date

2016-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proximal femoral fracture Osteoporosis

Interventions

Medication of recombinant human parathyroid hormone (teriparatide) by subcutaneous injection by oneself once a day for two years. control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: post operative patients with proximal femoral fractures over 65 years able to ambulate independently

Exclusion criteria

Exclusion criteria: Poor condition by suffering severe renal or heart disorder Not able to evaluate femoral CT imaging or DXA Having complication of secondary osteoporosis Having some medication for osteoporosis Having contraindication for teriparatide

Design outcomes

Primary

Measure	Time frame
Bone strength of proximal femur by CT/FEA	—

Secondary

Measure	Time frame
Bone material density of proximal femur Value of bone metabolism markers	—

Countries

Japan

Contacts

Public ContactAtsuhiro Tano

Saku Central Hospital Advanced Care Center Orthopaedic surgery

ctroffice@sakuhp.or.jp0267-62-8181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026